The alliance includes more than 45 cancer centers and academic institutions aiming to expand the use of precision medicine in oncology. At Dana-Farber, it will operate out of the Lank Center for Genitourinary Oncology.
Dana-Farber will work with Caris to develop biomarker-driven trials and improve patient care by leveraging big data, the health system said in a news release.
POA members have access to a comprehensive database and artificial intelligence platform used to develop standards for cancer profiling and molecular testing in oncology.
More articles on oncology:
Breast cancer death rates stop declining in younger women, study finds
Cleveland Clinic oncologist reflects on the evolution of cancer care: 4 notes
Dartmouth’s cancer center installs radiation vision cameras
Leave a Reply